What is IMMX stock price today?

IMMX (Immix Biopharma Inc) stock is trading at $9.85 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is IMMX stock going up or down today?

IMMX stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy IMMX stock now?

The decision to buy IMMX depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is IMMX a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for IMMX based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is IMMX stock overvalued or undervalued?

Use our DCF valuation calculator to determine if IMMX is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is IMMX's P/E ratio?

P/E ratio data for IMMX will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is IMMX's market cap?

IMMX (Immix Biopharma Inc) has a market capitalization of $0.51 billion, making it a small-cap stock.

What is IMMX's price to book ratio?

IMMX trades at a price-to-book (P/B) ratio of 5.45, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does IMMX pay dividends?

IMMX does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is IMMX's dividend yield?

IMMX does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is IMMX stock a good long-term investment?

IMMX's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is IMMX's revenue growth rate?

Revenue growth data for IMMX is available on our dashboard with detailed financial statement analysis.

Profitability metrics for IMMX are available on our dashboard with complete income statement analysis.

What are the risks of investing in IMMX?

Key risks for IMMX include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does IMMX compare to its competitors?

Compare IMMX to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize IMMX's performance and positioning.

What is IMMX's stock price target for 2026?

Our AI model provides price targets for IMMX based on fundamental analysis: Bull case $12.80 (+30%), Base case $11.33 (+15%), Bear case $8.87 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about IMMX?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for IMMX. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is IMMX's next earnings report?

IMMX reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

IMMX - Immix Biopharma Inc

NYSE * Health Care * Biotechnology

$9.85

+$0.16 (+1.65%)

About Immix Biopharma Inc

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

IMMX Key Statistics

Market Cap

$513.69M

P/B Ratio

5.45

EPS

$-0.89

Employees

How IMMX Compares to Peers

IMMX is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

N/A

of 5

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
IMMX(This stock)	$513.69M	N/A	0%	0.0%	-
AMGNAmgen Inc	$188.58B	24.6	0%	0.2%	vs AMGN
GILDGilead Sciences	$172.56B	20.5	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$111.93B	28.7	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$78.92B	18.0	0%	0.3%	vs REGN
BIIBBiogen Inc	$26.26B	20.4	-0%	0.1%	vs BIIB

Immix Biopharma Inc Company Information

Headquarters: California; U.S.A
Website: www.immixbio.com
Sector: Health Care
Industry: Biotechnology

Data Updated: April 15, 2026 at 2:26 AM EDT

Ready to invest in IMMX?

Commission-free trading available. Affiliate links.

IMMX Lician Score

5% confidence

4.0/10

Neutral

IMMX has a Lician Score of 4/10 (Average). Areas of concern: Growth.

value

5.0

growth

2.0

quality

5.0

momentum

5.0

safety

5.0

The Lician Score is a comprehensive 1-10 rating that evaluates IMMXacross five key dimensions: Value (valuation relative to sector),Growth (revenue and earnings trajectory),Quality (profitability and balance sheet strength),Momentum (price trends and analyst sentiment), andSafety (volatility and risk metrics).

IMMX Financial Snowflake

5-axis analysis across key investment dimensions

4.4/10

Neutral

5.0

Value

Valuation vs. sector peers

2.0

Growth

Revenue & earnings trajectory

5.0

Quality

Profitability & moat strength

5.0

Momentum

Price trends & analyst sentiment

5.0

Safety

Financial stability & risk

Upcoming Events for IMMX

Dashboard

Enter a ticker to analyze